Baltimore Company Launches Improved Test for Breast Cancer Treatment

Online, April 30, 2010 (Newswire.com) - CCCC Diagnostics, Inc., headquartered in Baltimore, Maryland, has launched the DirectHitTM Test Panel for Breast Cancer, a vastly improved diagnostic test for breast cancer

John Hughes, President and CEO of CCC Diagnostics, states, "Our new DirectHit Test Panel is the only test which can predict the responsiveness to two additional classes of chemotherapy drugs, taxanes and 5-FU. In addition, DirectHit significantly increases the predictive accuracy (85-90%) of the estrogen receptor test and accurately delivers the HER-2/neu test."

Given the crucial time window for effective breast cancer therapy, our new test panel is a significant step forward for physicians and their patients because the treatment will now have a higher probability of affecting the tumor," says David A. Van Echo, M.D., CCC Diagnostic's Medical Director.

"No longer must one breast cancer treatment fit all," says Mr. Hughes, which should be welcome news for physicians and their patients.